Schlieren, Switzerland, Nov. 29, 2018 (GLOBE NEWSWIRE) -- In a recent study published in ScienceAdvances, researchers in the Innovative Medicines and Early Development (IMED) Biotech Unit of
AstraZeneca used InSphero
3D InSightâ„˘ Human Islet Microtissues to evaluate the effects of antisense oligonucleotides (ASOs) on glucose-stimulated insulin secretion (GSIS) in human pancreatic beta-cells. A promising new class of therapeutic molecules, ASOs are short, chemically modified, single-stranded nucleic acids that can silence any gene product of interest. The AstraZeneca research team, headed by Dr. Carina Ă„mmĂ¤lĂ¤, Team Leader in Cardiovascular, Renal and Metabolism (CVRM) at IMED, engineered a novel targeted delivery approach for ASO uptake specifically by pancreatic beta-cells. They successfully demonstrated that the ASO target gene in beta-cells could be silenced without affecting gene expression in other cell types.
InSphero partners with pharmaceutical companies to provide comprehensive solutions and disease models for investigators engaged in type 1 and type 2 diabetes research and drug development. 3D InSightâ„˘ Islet Microtissue models are standardized primary islets that display homogeneous and native-like distribution of endocrine cells as well as uniform, long-term (> 28 days) and robust islet function. The 3D InSightâ„˘ Diabetes Discovery Platform is ideal for high-throughput and longitudinal studies of pancreatic islet function, regeneration, and preservation in health and disease.
To read the ScienceAdvances paper, â€śTargeted delivery of antisense oligonucleotides to pancreatic beta-cellsâ€ś, see: http://advances.sciencemag.org/content/4/10/eaat3386.
To learn more about the AstraZeneca IMED Biotech Unit, visit: https://www.astrazeneca.com/our-science/IMED.html.
For more information about InSphero, visit www.insphero.com.
Dr. Frank Junker
Chief Business Officer
Phone +41 44 5150490
Dr. Jan Lichtenberg
Chief Executive Officer
Phone +41 44 5150490
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSightâ„˘ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g, T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akuraâ„˘ technology underlying the companyâ€™s 3D InSightâ„˘ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akuraâ„˘ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
Karen Dowell InSphero AG 800-779-7558 firstname.lastname@example.org